The development of spontaneous factor VIII inhibitor post allo-SCT in the setting of either acute or acute exacerbation of chronic GVHD has been described in two case reports.
The development of spontaneous factor VIII inhibitor post allo-SCT in the setting of either acute or acute exacerbation of chronic GVHD has been described in two case reports. 1, 2 In these two cases, the patients responded to corticosteroids and in one case recombinant human factor VIII was given in conjunction with steroids. 1 Herein, we describe a 64-year-old female with a history of CLL 2 years after matched sibling donor peripheral SCT who was admitted to the hospital after developing large gluteal i.m. hematomas at BM biopsy sites. An activated prothrombin time (PTT) was prolonged (154 s, normal 25.0-37.0 s) with a normal PT and fibrinogen. Further testing detected a factor VIII inhibitor of 90.4 Bethesda units and decreased factor VIII of o0.5% (normal 50-150%). A PTT mixing study did show partial correction of PTT at 0 m time point (54.7 s), but at 60 m PTT was further prolonged (87.2 s). Treatment with prednisone (1 mg/kg per day) was initiated for 1 week and stopped upon patient's request due to a history of avascular necrosis. Initially, Rituximab was given weekly for 4 weeks with marked improvement in the patient's PTT (Figure 1 ), decrease in factor VIII inhibitor level (0.8 Bethesda units), resolution of hematomas and no further recurrence of bleeding. However, as her PTT remained elevated, a second 4-week course of rituximab was given. The patient's PTT normalized and factor VIII inhibitor was not detectable 28 weeks after rituximab was initiated.
Before the development of factor VIII inhibitor, our patient was treated for chronic, extensive and moderate GVHD involving lungs, musculoskeletal system, and liver with extracorporeal photophoresis and low-dose steroids. The patient did not experience any exacerbations of her GVHD and her CLL was in remission as confirmed by flow cytometry of peripheral blood at the onset of factor VIII inhibitor. Spontaneous development of factor VIII inhibitor can lead to serious bleeding complications in the context of GVHD in the allogeneic transplant setting. Recognizing this Ab-mediated response in association with GVHD and the use of new mAbs such as rituximab may provide an alternative to steroids as the mainstay of therapy. 
